(INNS)
XENTUZUMAB(SLE)
XENTUZUMAB(INNC)
IMMUNOGLOBULIN G1-LAMBDA1, ANTI-[HOMO SAPIENS IGF1 (INSULIN-LIKE GROWTH FACTOR 1, SOMATOMEDIN C) AND IGF2 (INSULIN-LIKE GROWTH FACTOR 2, SOMATOMEDIN A)], HUMANIZED MONOCLONAL ANTIBODY; GAMMA1 HEAVY CHAIN (1-447) [HUMANIZED VH (HOMO SAPIENS IGHV3-23*03 (88.80%) -(IGHD) -IGHJ5*01) [8.8.10] (1-117) -IGHG1*01, GM17,1 (CH1 (118-215), HINGE (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-215')-DISULFIDE WITH LAMBDA1 LIGHT CHAIN (1'-216') [HUMANIZED V-LAMBDA (HOMO SAPIENS IGLV1-40*01 (88.20%) -IGLJ2*01) [8.3.11] (1'- 110') -IGLC2*01 A43>G (154) (111'-216')]; DIMER (226- 226'':229-229'')-BISDISULFIDE, RECOMMENDED INN: LIST 76(WHO)
XENTUZUMABUM(INN)